AB
Aiolos Bio
Acquiredbiopharmaceuticals
respiratory-health
- Business Model
- B2B
- Total Funding
- $245.0M
- Last Round
- $245.0M Series AOct 2023
- Rounds
- 1
About
Respiratory illness and inflammatory condition treatments
Summary
Aiolos Bio is a biopharmaceuticals company. It has raised $245.0M in total across 1 round, most recently a $245.0M Series A round in Oct 2023. Investors include GlaxoSmithKline, Atlas Venture and Bain Capital Life Sciences.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Feb 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.